Outcomes of Ultimpro Testing Implementation for Patients With Unexplained Recurrent Implantation Failure: A Single‐Center Retrospective Cohort Study

Problem A proportion of patients with unexplained recurrent implantation failure (uRIF) may have endometrial immune dysregulation amenable to treatment. Ultimpro (Matrice lab Innove, Paris, France) is an endometrial immunophenotype test which identifies the absence or presence and type of immune dysregulation, proposing personalized protocol adjustments for a future embryo transfer (ET). Method of Study 2.5‐year single‐center retrospective cohort analysis of 121 patients who underwent Ultimpro testing as a pilot study (January 2021—May 2023). Group 1 included 93 patients with uRIF, and Group 2 included 28 patients without RIF. Outcomes from Group 1 were compared to Group 3, a control cohort of 94 uRIF patients, outcomes for Group 2 were compared to Canadian average ongoing pregnancy rates (OPR) per ET. Primary outcome was pregnancy >32 weeks or live birth. Statistical analyses included the Student t ‐test or Mann–Whitney U test for continuous variables and the Fisher exact test for categorical data. Results In Group 1, 46/93 (49.5%) patients had a successful pregnancy compared to control (31/94 [33%], p = 0.026); when stratifying for RIF severity, patients with ≥ 5 failed blastocyst transfers benefitted most from Ultimpro (21/38 [55.3%] vs. control 5/25 (20.0%), p = 0.0084). In Group 2, rates of OPR per ET with Ultimpro recommendations did not differ from outcomes for non‐RIF patients (9/28 [32.1%]; 95% CI: 0.15–0.52 vs. 46.2%). Conclusions In patients with uRIF, our preliminary findings suggest that application of Ultimpro recommendations was associated with a higher rate of successful outcomes; this was not the case for patients without RIF. These findings provide the rationale for an independent randomized controlled trial evaluating the large‐scale use of Ultimpro in patients with uRIF.